Flumatinib clinical trials
Includes 2 studies of Flumatinib mesylate.
How each study uses flumatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the flumatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 5
Jiangsu Hansoh Pharmaceutical Co., Ltd. (5) · Shenzhen Second People's Hospital (2) · The First Affiliated Hospital of Soochow University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Zhongda Hospital (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Flumatinib is the comparator. A study of two new drugs counts under both.
- 1Embibatinib · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion Jul 2029
Reaching primary completion within a year · 1
Studies that test flumatinib.
- Apr 2027A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhasePhase 4 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses flumatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)Not yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06530810Written as HS-10382+FlumatinibHow we know
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingPhase 4Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05367765Written as FlumatinibHow we know
- A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingPhase 4Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05353205Written as Flumatinib mesylate tablets (400mg)How we know
- Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT05071482Written as FlumatinibHow we know
- Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedPhase 2The First Affiliated Hospital of Soochow UniversityNCT05433532Written as FlumatinibHow we know
- The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP PatientsStatus unknownPhase 4Shenzhen Second People's HospitalNCT04933526Written as FlumatinibHow we know
- Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALLStatus unknownPhase 3Zhongda HospitalNCT04375683Written as FlumatinibHow we know
- Flumatinib in CML-CP Patients With Ph+ Post Imatinib FailureStatus unknownPhase 4Shenzhen Second People's HospitalNCT04677439Written as FlumatinibHow we know
- The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CMLCompletedPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT02204644Written as Flumatinib 600mg qdHow we know
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT02511340Written as Flumatinib mesylate tablet 600 mg qdHow we know
- A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT01503502Written as flumatinibHow we know
As the comparator · 1 — what is tested is compared with flumatinib
Codes
What other systems call flumatinib · ClinicalTrials.gg INT005734
- MeSH (NLM) C553360flumatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) R4009Y24AIFLUMBATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27287759flumatinibConfirmed FDA, NLM, Wikidata
- DrugBank DB11904One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553360 | flumatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | R4009Y24AI | FLUMBATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27287759 | flumatinib | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB11904 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.